HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting
Covered in this story
What has happened since
- MetLife is up 3.8% since this was published, 54 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on MetLife
- Evercore ISI: $96.2 → $106 by Aug 2027 · In Line via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MET yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on MetLife →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.